MAPK3 and cancer: EA has also been demonstrated to inhibit the activation of key signaling kinases, such as the phosphorylated form of STAT3, Akt kinase, and ERK1/2, thereby leading to the inhibition of the PI3K/Akt/mTOR pathway, which is often overactive in cancer cells.